
TSE:MFC
This summary was created by AI, based on 27 opinions in the last 12 months.
Manulife Financial (MFC) has recently reported strong quarterly results, demonstrating solid performance in its operations, particularly in Hong Kong and Asia. However, the imposition of taxes by the Chinese government on MFC's products for mainland residents has raised concerns among investors. The company's valuation remains a topic of discussion, with some experts suggesting that MFC may be overbought and perceiving the financial sector in Canada as a whole to be slightly overvalued. While many analysts see potential in MFC due to its strong dividend yields and growth prospects, especially in Asia and wealth management, caution is advised regarding market conditions and potential pullbacks. Analysts recommend further observation of market dynamics, suggesting advantageous entry points should significant price corrections occur.
Sometimes people run for cover when there's a short-seller. In this case, the short-seller has picked up on a lawsuit over a 20-year-old insurance policy which he thinks doesn't have merit. The market has sold first and asked questions
later. After the pullback, the stock has regained 15% and has created a great entry point now. Trading at 1x book value, deeply discounted. 12% ROE, so profitability is solid. Geographically diverse between Canada-U.S.-Asia. Their
welath and asset management division is their golden child, growing nicely. The only weakness is their US legacy business, but they're cleaning it up. The stock should be much higher. (4.36% dividend, Analysts Price Target $29.59)
It's hard making money owning it. He's not sure why Canadians keep banging their head buying MFC, when you can buy the Canadian banks. He has no specific criticism about MFC, and in fact MFC is doing a lot of things right, like
moving more into wealth management and performing well in Asia, while diversifying away from insurance. But there's a disconnect in what they're doing and the share price, which has been ongoing.
It is incredibly cheap and has been looking at it the last few weeks. There was a short report out this week saying that there was this legacy litigation issue that was not properly disclosed. The bigger problem for them is they have a number of legacy businesses that are lower return on equity that they have to rotate out of. Nothing fundamentally wrong with it.
He has long owned this. He expects good Asian earnings and that they will hike the dividend. Even the short-seller Muddy Waters says the court case (that they've written about) is a binary issue and MW could lose in the end. MFC has been doing this a long time, and hopes the management will pull through.
(A Top Pick October 5/17 Down 17%) This was his pick for a rising interest rate environment. A lawsuit is pending to allow an investor to allow unlimited funds into an income investment, which would create severe losses and impact the balance sheet. So far the company is ignoring the investor suit. He interviewed management recently and they intend to vigorously defend their position. He is going to stick with it.
Short-seller Muddy Waters is about a specific legal case in progress. Strong franchise in Asia, but what's hurting them is their John Hancock franchise in the U.S. with a low ROE. Have a strong asset management business. MFC must deal with Hancock--can't sell it but must improve ROE. Management is slowly doing that. Now is a good buying opportunity with a good yield. Could take time.
She has no more info about the Muddy Waters short report. Muddy is betting on the outcome of this trial. See what happens. It could drag on for years with appeals. She likes the new CEO who has segmented their legacy products, and likes their positioning in China. It's now trading close to book value.
A short report from Muddy Waters came out today. He's always liked MFC. Universal life policies and the way they were funded is what got them in trouble in 2008. He thought they'd walked away from this problem, and now he is not 100% sure they have. He needs to read this short report closely. Don't short or sell it, but he expects this to underperform for a while.
MFC has often been his top pick. For lifecos operating in the U.S. there are accouting issues between Canada and America in how they account for reserves. There is embedded value in MFC's long-term care assets that aren't reflected in the stock price. Now is a buying opportunity. He expects their next report to be fine.